| |
|
Rita Nahta, Ph.D. |
|
Assistant Professor |
|
| |
|
|
|
|
|
| |
|
|
Emory University School of Medicine |
|
| |
|
|
Winship Cancer Institute, Room C4008 |
|
| |
|
|
1365-C Clifton Road |
|
| |
|
|
Atlanta, GA 30322 |
|
| |
|
|
Tel: 404-778-3097 |
|
| |
|
|
Tel: 404-778-3064 (Lab) |
|
| |
|
|
Fax: 404-728-5530 |
|
| |
|
|
rnahta@emory.edu |
|
| |
|
|
|
|
| |
|
|
Ph.D., Duke University, 2000 |
|
| |
|
|
Postdoctoral Fellow, Harvard Medical School, 2000-2002 |
|
| |
|
|
|
Postdoctoral Fellow, M.D. Anderson Cancer Center, 2002-2004 |
|
| |
|
|
|
Instructor, M.D. Anderson Cancer Center, 2004-2007 |
|
| |
|
|
|
Assistant Professor, Emory University, 2007-present |
|
| |
|
Research Interest: |
|
|
|
| |
|
|
|
|
|
| |
|
Growth factor signaling and drug resistance in breast cancer
Our laboratory studies the mechanisms by which HER2-over-expressing metastatic breast cancers develop resistance to the clinically approved HER2-targeted agents trastuzumab and lapatinib. By elucidating these mechanisms, we can identify novel molecular targets against which drugs can be developed. In addition, we are studying novel drug combinations to be used in HER2-over-expressing breast cancers, including those cancers that have progressed on existing HER2-targeted therapies.
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
|
